- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 06.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | 174 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the "Company"... ► Artikel lesen | |
| 06.08. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit | 1 | GlobeNewswire (USA) | ||
| 01.07. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment | 3 | Investing.com | ||
| 24.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | 499 | GlobeNewswire (Europe) | - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE... ► Artikel lesen | |
| 22.06. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news | 1 | Investing.com | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 16.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045 | 577 | GlobeNewswire (Europe) | PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 04.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis | 462 | GlobeNewswire (Europe) | - Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage... ► Artikel lesen | |
| 21.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 14.05. | Cognition Therapeutics receives donation to extend DLB program | 2 | Investing.com | ||
| 14.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 08.05. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cognition Therapeutics GAAP EPS of -$0.05 beats by $0.02 | 5 | Seeking Alpha | ||
| 07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | 982 | GlobeNewswire (Europe) | Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Cognition Therapeutics plant entscheidende Studie für Demenz-Wirkstoff | 3 | Investing.com Deutsch | ||
| 31.03. | Cognition Therapeutics plans late-stage trial for dementia drug | 1 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,05 | +2,87 % | Biontech: Viel Lob für die Ergebnisse | Auf einem Lungenkrebs-Kongress stellt Biontech zwei neue Studienergebnisse vor. Dabei geht es einerseits um Gotistobart. Hier zeigt sich fast eine Verdopplung der Überlebenszeit im Vergleich zur Standardchemotherapie.... ► Artikel lesen | |
| AMGEN | 342,65 | +2,07 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 9,210 | +4,78 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 193,00 | +2,85 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| CLINUVEL | 5,028 | -1,14 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| VIKING THERAPEUTICS | 24,900 | -1,39 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,720 | +1,32 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 68,44 | +1,00 % | Goldman Sachs startet Coverage für Tempus AI Aktie mit "Neutral"-Rating | ||
| BIOCRYST PHARMACEUTICALS | 7,680 | +2,54 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,399 | +0,76 % | Breaking News: Weiche zur Nasdaq gestellt | ||
| BIOMARIN PHARMACEUTICAL | 55,92 | +0,47 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen | |
| EXELIXIS | 51,33 | +1,06 % | Citizens reiterates Exelixis stock rating on FDA review extension | ||
| SAREPTA THERAPEUTICS | 17,560 | +0,11 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,662 | +1,84 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,201 | +1,05 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,33 % bei einem Aktienkurs von 1,015 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.